Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation

Anti-Cancer Drugs

Volumn 19, Issue 10, 2008, Pages 975-981

  Kwee, Jolie Kiemlian ^a   Luque, Diogo Gomes ^a   Ferreira, Ana Carolina Dos Santos ^a   Vasconcelos, Flavia Da Cunha ^a   Silva, Karina Lani ^a   Klumb, Claudete Esteves ^a   Maia, Raquel Ciuvalschi ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Apoptosis; Catalase; Chronic myelogenous leukemia; Imatinib; Oxidative stress; Survivin

Indexed keywords

ANTIOXIDANT; CATALASE; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE; SURVIVIN;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

AMITROLE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BUTHIONINE SULFOXIMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PIPERAZINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES;

EID: 54249133182     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283140c6f     Document Type: Article

References (32)

1. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004; 22:247-306.
2. Wang Z, Sampath J, Fukuda S, Pelus LM. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res 2005; 65:8224-8232.
3. Krause DS, van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-187.
4. Schenone S, Manetti F, Botta M. Last findings on dual inhibitors of Abl and Src tyrosine-kinases. Mini Rev Med Chem 2007; 7:191-201.
5. Roskoski R Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 2003; 309:709-717.
6. Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 2007; 12:327-340.
7. Hochhaus A, Rosée PL. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18:1321-1331.
8. Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program 2006; 10:219-225.
9. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275:24273-24278.
10. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, Gloc E, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004; 104:3746-3753.
11. Jin HO, Yoon SI, Seo SK, Lee HC, Woo SH, Yoo DH, et al. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. Biochem Pharmacol 2006; 72:1228-1236.
12. Scheper MA, Nikitakis NG, Chaisuparat R, Montaner S, Sauk JJ. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia 2007; 9:192-199.
13. Seo SK, Lee HC, Woo SH, Jin HO, Yoo DH, Lee SJ, et al. Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis 2007; 12:195-209.
14. Kwee JK, Mitidieri E, Affonso OR. Lowered superoxide dismutase in highly metastatic B16 melanoma cells. Cancer Lett 1991; 57:199-202.
15. Kwee JK, Armelin MS, Stefani HA, Augusto O. Cell proliferation induced by 8-oxoguanosine and 8-methylguanosine, two adducts produced by free radical attack on ribonucleosides and RNA. Chem Biol Interact 1998; 116:61-77.
16. Giles GI. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006; 12:4427-4443.
17. Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: breath of life or death? Clin Cancer Res 2007; 13:789-794.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
19. Aebi H. Catalase in vitro. Meth Enzymol 1984; 105:121-126.
20. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254:7558-7560.
21. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1980; 130:1910-1917.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J Immunol Methods 1983; 65:55-63.
23. Silva KL, Vasconcellos DV, Castro EDP, Coelho A M, Linden R, Maia RC. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukaemia. Apoptosis 2006; 11:277-285.
24. Konig H, Härtel N, Schultheis B, Schatz M, Lorentz C, Melo JV, et al. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells. Haematologica 2007; 92:838-841.
25. Conte E, Stagno F, Guglielmo P, Scuto A, Consoli C, Messina A. Survivin expression in chronic myeloid leukemia. Cancer Lett 2005; 225:105-110.
26. Jing Y, Dai J, Chalmers-Redman RME, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94:2102-2111.
27. Brunelli L, Yermilov V, Beckman JS. Modulation of catalase peroxidatic and catalatic activity by nitric oxide. Free Rad Biol Med 2001; 30:709-714.
28. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DD, Insenberg JS. The biphasic nature of nitric oxide responses in tumor biology. Antiox Redox Signal 2006; 8:1329-1337.
29. Maccarrone M, Fantini C, Ranalli M, Melino G, Agrò AF. Activation of nitric oxide synthase is involved in tamoxifen-induced apoptosis of human erythroleukemia K562 cells. FEBS Lett 1998; 434:421-424.
30. Chao JI, Kuo PC, Hsu TS. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem 2004; 279:20267-20276.
31. Kondo T, Suzuki Y, Kitano T, Iwai K, Watanabe M, Umehara H, et al. Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis. Mol Pharmacol 2002; 61:620-627.
32. Rosée PL, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30:729-737.